Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

November 13, 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

January 30, 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

January 29, 2019

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

November 09, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

February 13, 2018

Next-Generation Large-Bore Closure Devices Arrive

News Conference News ISET 2018

Next-Generation Large-Bore Closure Devices Arrive

February 05, 2018

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.